Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment “Stemchymal®”

Corporate News

YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…

2nd Global Biologics India 2025

Upcoming Events

📅 Date: 16-17 April 2025 📍 Venue: Hotel Le Meridien, Hyderabad, India Join us at 2nd Global Biologics India 2025, a premier conference bringing together leading experts, researchers, and industry pioneers in Cell and Gene Therapy (CGT), mAbs, and Biosimilars. This two-day event will feature insightful keynote speeches, panel discussions, and networking opportunities with top…

Oligosynthesis

Custom DNA Oligonucleotide Synthesis Services: Precision Tools for Molecular Success

Blogs

Custom DNA Oligonucleotide Synthesis Services: Precision Tools for Molecular Success In modern molecular biology, custom DNA oligonucleotides (or “oligos”) are indispensable tools used in diagnostics, gene editing, synthetic biology, and research. As the demand for personalized, high-quality DNA sequences grows, so does the need for reliable custom oligo synthesis services tailored to specific experimental needs.…

5th Annual Summit of Biologics Conferences and Workshop on Biopharmaceutical Product Development

Upcoming Events

Come and Meet Us at the Following Conference 5th Annual Summit of Biologics Conferences and Workshop on Biopharmaceutical Product Development Date: January 30-31, 2025Venue: Novotel Dona Sylvia Resort, Goa, India The Biologics Conference and Workshop 2025, conducted by the Mumbai Biocluster, is a landmark event designed to foster innovation, networking, and collaboration within the biopharmaceutical…

World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

Corporate News

REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology. This major medical advancement marks a pivotal breakthrough in redefining women’s healthcare, supported by our StemRNA™ Clinical induced Pluripotent Stem Cells (iPSCs).

Qkine announces partnership with REPROCELL

Corporate News

Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture Cambridge, UK and Yokohama, Japan – Qkine Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, and REPROCELL Inc., Japan’s first and leading induced pluripotent stem cell (iPSC) company, have partnered to globally…